Medline Inc. (MDLN) Next Earnings Date & Expected ±6.2% Move

Per the Roarable RQD rating, MDLN scores 44 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC 8.2%; FCF yield 3.08%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 11/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.11; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 2.5; Piotroski F 5/9; Debt/Equity 1.16).

Taken together, the pillars indicate weak scores across cash generation, institutional flow, and macro fit, with the balance sheet scoring highest of the five but still below half of its weight. For a prospective investor evaluating the stock today, the rating points to a limited set of upside drivers in the source data and a cautionary posture on the rating's own terms. The 3.08% FCF yield and 8.2% ROIC are the figures the rating cites as the core cash-engine evidence; the 1.11 beta indicates above-market sensitivity to broad moves, and the rating treats that as a macro-fit weakness. The valuation tradeoff is visible in the EV/EBITDA of 20.3 set against the 7.8% operating margin: the source data does not state a P/E, so the rating's implications for earnings-based valuation cannot be assessed. This section is educational and does not constitute personalized financial advice.

Per the SEC financials, revenue rose from $23231.0M (FY 2023) to $28432.0M (FY 2025), while operating income moved from $1250.0M to $2212.0M over the same span. The FY 2025 net income figure of $1157000.0M is an outlier relative to operating income and is not reconciled in the source data; the FY 2024 and FY 2023 net income entries of $0.0M likewise do not reconcile. The market data reports an operating margin of 7.8%, a net margin of 68%, and a gross margin of 0%; these margin values are not internally consistent with the reported revenue and income lines and should be treated with caution. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with Debt/Equity at 1.16. Reported debt declined from $16416.0M (FY 2024) to $12484.0M (FY 2025), and cash rose from $199.0M to $1939.0M.

• RISK WATCH (RED): A headline reports a securities fraud probe following a 13% stock drop.
• MARKET WIRE (YELLOW): A PR Newswire item ties the 13% decline to disclosed product quality issues and an underway securities fraud investigation.
• MARKET WIRE (YELLOW): An Investing.com item reports a sale of $274.8 million in MDLN shares by GIC Private Ltd.
• MARKET WIRE (YELLOW): A Stock Titan item reports a 10% owner sale with a reported indirect position of 69.4M shares afterward.
• MARKET WIRE (YELLOW): A Seeking Alpha item carries the headline "Beware The Private Equity Overhang."
• MARKET WIRE (YELLOW): A Quiver Quantitative item reports $80,000 of lobbying disclosed.

The Butterfly Supply-Chain Graph reports no supply chain and no links or proprietary signals, so no proprietary supply-chain catalysts are available in the source data.

• What is the scope and status of the reported securities fraud investigation, and what product quality issues underlie the 13% decline?
• Why do the reported net income figures ($1157000.0M for FY 2025 and $0.0M for FY 2024 and FY 2023) fail to reconcile with operating income, and what are the correct EPS values?
• What are the company's principal products, customers, and revenue model?
• What is the terms and effect of the reported private equity overhang on float and share supply?
• What is the analyst consensus, price target range, and institutional 13F holder breakdown?